The European Commission (EC) has granted approval to Takeda for ADZYNMA (recombinant ADAMTS13) - the first and only enzyme replacement therapy in the European Union (EU) for congenital thrombotic ...
Progress is being made on the British Army's Collective Training Transformation Programme (CTTP) that aims to deliver a Future Collective Training System (FCTS) in 2025. The Collective Training ...
Takeda has reported positive results from a phase 3 trial of its experimental therapy TAK-755 for ultra-rare disease congenital thrombotic thrombocytopenic purpura (cTTP), setting up regulatory ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has ...
− cTTP is an Ultra-rare, Potentially Fatal Blood-Clotting Disorder with Limited Treatment Options; Untreated, Acute TTP Events Have a Mortality Rate of >90%1,2 − Approval Based on Totality of Evidence ...
Elbit UK continues to grow its UK defence programme portfolio with the award of the ICAVS(D) programme, a pathfinder for CTTP. Elbit Systems UK has been selected to deliver the Interim Combined Arms ...
cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic Symptoms Takeda Continues 70-plus Year Legacy of Driving Innovation for the Rare ...
Congenital thrombotic thrombocytopenic purpura (TTP), an ultra-rare disease, can significantly impact quality of life, but clinicians have previously lacked a disease-specific way to track experiences ...
"People living with cTTP experience serious, potentially fatal health challenges and have limited treatment options in the European Union," said Obi Umeh, M.D., M.Sc., Vice President, Franchise Global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results